NEW YORK (GenomeWeb News)– Myriad Genetics disclosed last week that Crescendo Bioscience recorded $27.3 million in revenues and a net loss of $41.1 million in 2013. Myriad acquired the autoimmune diagnostics company for $245 million in March. Crescendo spent $12.1 million on R&D last year and $26.4 million on SG&A. It ended the year with $3.1 million in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.